Recognized industry leaders Richard Champlin, John Hood and Andrew Lowy join Cytonus’ Scientific Advisory Board
SAN DIEGO (PRWEB) JANUARY 12, 2020
It is a great privilege for our Cytonus team to be joined by such esteemed Key Opinion Leaders, each of whom has contributed important advances in the field of medicine.
Cytonus Therapeutics Inc. today announces the formation of its Scientific Advisory Board (SAB) comprised of the industry’s key opinion leaders and distinguished research scientists, collectively representing prestigious academic institutions, immune-oncology centers, cell therapy centers, and private industry. Cytonus is a leading cell-based platform technology company focused on the development of a vast pipeline of proprietary cell lines called Cargocytes™, the next-generation of Adoptive Cellular Therapies (ACT) that have a wide range of medical applications across multiple therapeutic areas including immunotherapeutic products to cure difficult-to-treat cancers and inflammatory diseases, and to improve patient outcomes. Cytonus’ products have the potential to improve the health and lives of millions of people across the globe.
“It is a great privilege for our Cytonus team to be joined by such esteemed Key Opinion Leaders, each of whom has contributed important advances in the field of medicine,” commented Cytonus’ Founder and Chief Scientific Officer, Richard Klemke, PhD.
“The expertise and multi-disciplinary scientific perspectives of Dr. Hood, Dr. Lowy and Dr. Champlin will accelerate the advancement of Cytonus’ pipeline,” commented Cytonus’ Founder and CEO Remo Moomiaie-Qajar, MD.
The inaugural members of Cytonus’ Scientific Advisory Board are: Richard Champlin, MD; John Hood, PhD; and Andrew Lowy, MD.
- Richard Champlin, MD is the Chair of MD Anderson Cancer Center’s Cellular Therapy Department. He also serves as Professor of Internal Medicine at University of Texas Health Science Center and is a Scientific Advisor for StemRad. Previously, in addition to serving on the President’s Advisory Board, Dr. Champlin has served as the Director of Transplantation Biology at UCLA’s Center for Health Sciences. He was the Founding President of the American Society of Blood and Marrow Transplantation, and is former President of the National Marrow Donor Program’s Council for Donor, Transplant and Collection Centers. Professor Champlin has received numerous industry recognitions, including: the Giannini Foundation Fellowship Award, the Waun Ki Hong Award for Excellence in Team Science; the Robert C. Hickey Chair in Clinical Cancer Care Award, and the G.A. Ross Scholarship Award.
- John Hood, PhD was Founder and Chief Executive Officer of Impact Biomedicines, which he successfully sold to Celgene for up to $7 Billion. He was also a founder of Endeavor Biomedicines, Neuronomix, and Samumed, where he advanced regenerative medicine and oncology therapies. Previously, Dr. Hood served as Director of Research at TargeGen, which sold to Sanofi SA after he co-invented its small molecule inhibitor, now known as fedratinib. Dr. Hood is a prolific inventor with more than 100 patents and has authored more than 100 scientific articles. He received both his PhD and Bachelor’s degree at Texas A&M University.
- Andrew Lowy, MD is the Chief of Surgical Oncology at UC San Diego, Moores Cancer Center. He is a distinguished surgical oncologist who is recognized worldwide for his expertise in the surgical treatment of gastrointestinal cancers. He is a key contributor to the development of heated intraperitoneal chemotherapy (HIPEC) to treat peritoneal based cancers. Dr. Lowy is the Co-Chair of the National Cancer Institute’s Pancreatic Cancer Task Force; serves as surgical liaison to one of the largest National Cancer Institute cooperative groups; and serves on the editorial board of the Annals of Surgical Oncology.
About Cytonus Therapeutics Inc.
Cytonus Therapeutics Inc. is a San Diego based biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyte™ technologies are next-generation biomolecular delivery devices which have numerous medical applications across unmet therapeutic areas. Cargocytes™ are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable “off-the-shelf” therapies. Cytonus’ vast platform of therapeutics and vaccines has the potential to improve the health and lives of people with life-threatening conditions. For more information, we invite you to visit the Cytonus website at https://Cytonus.com. Please follow us on Cytonus on LinkedIn and on Twitter at: @CytonusTx.
Statements in this news release other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words “believe,” “expect,” “aim,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.
Join Cytonus on LinkedIn and follow its Twitter account at: @CytonusTx